2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Wednesday, September 25, 2019

1:15pm-2:45pm: Establishing the first apomorphine treatment registry in Thailand: prospective data collection to inform optimal care of Parkinson’s disease patients

R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, T. Boonmongkol, Y. Thongchuam, N. Kantachadvanich, J. Sringean, P. Panyakaew, P. Jagota (Bangkok, Thailand)

Epidemiology · Les Muses, Level 3

1:15pm-2:45pm: Evaluating Perceptions of Deep Brain Stimulation in DBS-naïve Patients with Parkinson’s Disease – A Pilot Study

S. Das, S. Ramesh, M. Baldassari, M. Rasool, J. Ratliff, D. Kremens, T. Alexander, C. Matias, TW. Liang, C. Wu (Philadelphia, PA, USA)

Surgical Therapy · Les Muses Terrace, Level 3

1:15pm-2:45pm: Evaluating Volume Changes in the Substantia Nigra Pars Compacta (SNc) in Parkinson’s Disease (PD) in a Study-Specific Magnetic Resonance Imaging (MRI) Template

E. Biondetti, R. Gaurav, L. Yahia-Cherif, G. Mangone, N. Pyatigorskaya, R. Valabregue, C. Ewenczyk, M. Hutchison, JC. Corvol, MJ. Vidailhet, S. Lehéricy (Paris, France)

Neuroimaging · Les Muses Terrace, Level 3

1:15pm-2:45pm: Evaluation of Device-Assisted Treatment using a wearable accelerometry wrist sensor

A. Johansson, M. Lundgren, M. öthman, D. Nyholm (Stockholm, Sweden)

Phenomenology and Clinical Assessment of Movement Disorders · Les Muses Terrace, Level 3

1:15pm-2:45pm: Evaluation of gut microbiota in patients with Parkinson’s disease using a gas chromatography–mass spectrometry in Russia

I. Krasakov, I. Litvinenko (Saint-Petersburg, Russian Federation)

Non-Motor Symptoms · Agora 3 West, Level 3

1:15pm-2:45pm: Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Huntington’s Disease: An in vivo [11C]BU99008 PET study

H. Wilson, F. Niccolini, G. Dervenoulas, R. Tyacke, J. Myers, R. Gunn, D. Nutt, E. Rabiner, S. Tabrizi, M. Politis (London, United Kingdom)

Neuroimaging · Les Muses Terrace, Level 3

1:15pm-2:45pm: Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study

H. Wilson, G. Dervenoulas, G. Pagano, R. Tyacke, J. Myers, R. Gunn, E. Rabiner, D. Nutt, M. Politis (London, United Kingdom)

Neuroimaging · Les Muses Terrace, Level 3

1:15pm-2:45pm: Evaluation of nigral neuronal apoptosis during postnatal development and adulthood of mice strains with differential sensitivity to MPTP

Y. H, V. Dj, C. Sagar, R. Tr, P. Alladi (Bangalore, India)

Physiology and Pathophysiology · Les Muses, Level 3

1:15pm-2:45pm: Evaluation of the Zeez Sleep Pebble for Sleep Disturbance in Parkinson’s Disease

S. Milne, S. Cummins, C. Carroll (Plymouth, United Kingdom)

Non-Motor Symptoms · Agora 3 West, Level 3

1:15pm-2:45pm: Evidence of altered Serotonergic Network in Parkinson’s disease by using a multi-modal MRI and PET imaging approach

SP. Caminiti, Z. Chappell, A. Carotenuto, G. Dervenoulas, T. Yousaf, G. Pagano, H. Wilson, M. Politis (London, United Kingdom)

Neuroimaging · Les Muses Terrace, Level 3